<SEC-DOCUMENT>0001193125-21-142782.txt : 20210430
<SEC-HEADER>0001193125-21-142782.hdr.sgml : 20210430
<ACCEPTANCE-DATETIME>20210430084528
ACCESSION NUMBER:		0001193125-21-142782
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20210430
DATE AS OF CHANGE:		20210430

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMGEN INC
		CENTRAL INDEX KEY:			0000318154
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				953540776
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37702
		FILM NUMBER:		21873973

	BUSINESS ADDRESS:	
		STREET 1:		ONE AMGEN CENTER DRIVE
		CITY:			THOUSAND OAKS
		STATE:			CA
		ZIP:			91320
		BUSINESS PHONE:		(805)447-1000

	MAIL ADDRESS:	
		STREET 1:		ONE AMGEN CENTER DRIVE
		CITY:			THOUSAND OAKS
		STATE:			CA
		ZIP:			91320

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMGEN
		DATE OF NAME CHANGE:	19870305
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>d173656ddefa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML><HEAD>
<TITLE>DEFA14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="center">Washington,
D.C. 20549 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:15pt; font-family:arial" ALIGN="center"><B>SCHEDULE 14A INFORMATION </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="center"><B>Proxy Statement Pursuant to Section 14(a) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="50%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman; font-size:14pt">&#9745;</FONT>&nbsp;&nbsp;Filed by the registrant&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman; font-size:14pt">&#9744;</FONT>&nbsp;&nbsp;Filed by a party other than the registrant</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR BGCOLOR="#d8e7f6" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" COLSPAN="5" STYLE="BORDER:1px solid #000000; padding-left:8pt; padding-right:2pt"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial"><B>Check the appropriate box:</B></P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman; font-size:14pt">&#9744;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">Preliminary Proxy Statement</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT STYLE="font-family:Times New Roman; font-size:14pt">&#9744;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL">CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY&nbsp;(AS PERMITTED BY RULE 14A-6(E)(2))</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT STYLE="font-family:Times New Roman; font-size:14pt">&#9744;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">Definitive Proxy Statement</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT STYLE="font-family:Times New Roman; font-size:14pt">&#9745;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">Definitive Additional Materials</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="4" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT STYLE="font-family:Times New Roman; font-size:14pt">&#9744;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">Soliciting Material Pursuant to Section 240.14a-12</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:arial" ALIGN="center"><FONT COLOR="#0063c3"><B>AMGEN INC. </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:11pt; font-family:arial" ALIGN="center"><I>(Name of Registrant as Specified in Its Charter) </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:arial" ALIGN="center"><I>(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR BGCOLOR="#d8e7f6" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" COLSPAN="5" STYLE="BORDER:1px solid #000000; padding-left:8pt; padding-right:2pt"> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial"><B>Payment of filing fee (check the appropriate box):</B></P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman; font-size:14pt">&#9745;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</P> <P STYLE="font-size:5pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="justify"><B>No fee required.</B></P> <P STYLE="font-size:5pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:14pt">&#9744;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;</P> <P STYLE="font-size:5pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="justify"><B>Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11</B></P>
<P STYLE="font-size:5pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">(1)&#8201;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.26em; text-indent:-1.26em; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">Title of each class of securities to which transaction applies:</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">(2)&#8201;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.26em; text-indent:-1.26em; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">Aggregate number of securities to which transaction applies:</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL">(3)&#8201;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Per unit price or
other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">(4)&#8201;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.26em; text-indent:-1.26em; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">Proposed maximum aggregate value of transaction:</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">(5)&#8201;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.26em; text-indent:-1.26em; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">Total fee paid:</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT STYLE="font-family:Times New Roman; font-size:14pt">&#9744;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="font-size:5pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="justify"><B>Fee paid previously with preliminary materials.</B></P> <P STYLE="font-size:5pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT
STYLE="font-family:Times New Roman; font-size:14pt">&#9744;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL"><B>Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the&nbsp; offsetting fee was paid
previously. Identify the previous filing by registration statement number, or the Form or Schedule&nbsp; and the date of its filing.</B></P> <P STYLE="font-size:5pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">(1)&#8201;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.26em; text-indent:-1.26em; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">Amount Previously Paid:</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">(2)&#8201;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.26em; text-indent:-1.26em; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">Form, Schedule or Registration Statement No.:</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">(3)&#8201;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.26em; text-indent:-1.26em; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">Filing Party:</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">(4)&#8201;</P>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.26em; text-indent:-1.26em; font-size:9.5pt; font-family:ARIAL" ALIGN="justify">Date Filed:</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10.5pt; font-family:Times New Roman" ALIGN="center">[Subsequent to this filing, the following letter was sent by Amgen Inc. to certain
institutional holders of our common </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10.5pt; font-family:Times New Roman" ALIGN="center">stock. We encourage our stockholders to similarly consider this letter when casting their vote.] </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g173656g0429155138547.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">April&nbsp;30, 2021 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman">&laquo;SALUTATION&raquo; &laquo;FIRSTNAME&raquo; &laquo;LASTNAME&raquo; </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman">&laquo;COMPANYNAME&raquo; </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman">&laquo;ADDRESS1&raquo; </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman">&laquo;ADDRESS2&raquo; </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman">&laquo;CITY&raquo;, &laquo;STATE&raquo;
&laquo;ZIPCODE&raquo; </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Dear &laquo;SALUTATION&raquo; &laquo;LASTNAME&raquo;: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">I want to take a moment to thank you for your investment in Amgen. I typically write around this time of year to provide a
short summary of Amgen&#146;s Board of Directors&#146; recommendations for our 2021 Annual Meeting of Stockholders. As I know many are continuing to work remotely, I&#146;m sending this communication electronically again this year. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify"><FONT COLOR="#0070c0"><B>2020 Was an Unprecedented Year. </B></FONT></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:8%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">2020 was a year like no other in Amgen&#146;s <FONT STYLE="white-space:nowrap">40-year</FONT> history. We experienced a global
pandemic, worldwide economic disruption, and widespread social unrest, yet continued to deliver for patients. In a year that brought health and safety sharply into focus, as a leading global healthcare company and responsible corporate citizen,
Amgen committed to helping to address the pandemic. During 2020, we prioritized the safety and well-being of our employees, maintained supply of our medicines to patients, contributed resources to the fight against
<FONT STYLE="white-space:nowrap">COVID-19,</FONT> and helped support those in need in the communities where we live and work. For information on our evolving response to this unprecedented situation, please visit <I></I><FONT
STYLE="font-family:Times New Roman" COLOR="#0070c0"><B></B><I><FONT STYLE="white-space:nowrap">www.amgen.com/COVID-19</FONT></I><B></B></FONT><FONT STYLE="font-family:Times New Roman"><I></I><SUP STYLE="font-size:85%; vertical-align:top">(</SUP><SUP
STYLE="font-size:85%; vertical-align:top">1</SUP><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>. </FONT></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify"><FONT COLOR="#0070c0"><B>Our Commitment to Society. </B></FONT></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:8%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">As part of our mission to serve patients, we take our
<B><FONT STYLE="font-family:Times New Roman" COLOR="#0070c0">environmental sustainability</FONT></B>,<B> <FONT STYLE="font-family:Times New Roman" COLOR="#0070c0">social responsibility</FONT></B>, and <B><FONT
STYLE="font-family:Times New Roman" COLOR="#0070c0">corporate governance responsibilities</FONT></B> to heart. </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; " COLOR="#0070c0">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">After achieving our 2013-2020 conservation targets, in January, we launched our<FONT COLOR="#0070c0"><B> new
environmental sustainability plan</B></FONT> that includes a goal of achieving carbon neutrality in our owned and operated facilities by 2027 (while also reducing water use by 40% and waste disposed by 75%<SUP
STYLE="font-size:85%; vertical-align:top">(</SUP><SUP STYLE="font-size:85%; vertical-align:top">2</SUP><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>). </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; " COLOR="#0070c0">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">Since its inception, The Amgen Foundation, Inc., a separate legal entity entirely funded by Amgen, has
contributed more than <B><FONT COLOR="#0070c0">$350</FONT>&nbsp;<FONT COLOR="#0070c0">million to <FONT STYLE="white-space:nowrap">non-profit</FONT> organizations</FONT></B> across the world that reflect our core values and complement Amgen&#146;s
purpose-driven dedication to impacting lives in inspiring and innovative ways. </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; " COLOR="#0070c0">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">Through patient assistance programs, expanded access to investigational therapies, donations, and other
efforts, we have developed patient support programs worldwide to <B><FONT COLOR="#0070c0">assist eligible patients to obtain the medicines they need</FONT></B>.<B></B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; " COLOR="#0070c0">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">We increased our focus on <B><FONT COLOR="#0070c0">diversity</FONT></B>,<B>
<FONT COLOR="#0070c0">inclusion</FONT></B>,<B> <FONT COLOR="#0070c0">and belonging</FONT></B>, including by becoming a founding member of OneTen, a coalition of more than 40 of the world&#146;s largest, best-known companies, that aims collectively
to hire one million Black Americans (with a specific focus on those without four-year college degrees) into good-paying, family-sustaining jobs over the next ten years, and as a founding sponsor of Lazarex Cancer Foundation&#146;s IMPACT (Improving
Patient Access to Cancer Clinical Trials) program, focused on improving patient enrollment, minority participation, and equitable access in cancer clinical trials. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #5c6267;width:21%">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP> Reference to our website is not intended to function as a hyperlink and the information contained on
our website is not intended to be part of this letter. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP> Reductions take into account only verified
reduction projections, and do not take into account changes associated with the contraction or expansion of the Company. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify"><FONT COLOR="#0070c0"><B>Our Board. </B></FONT></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:8%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Our Board includes three women and two diverse directors and has strong refreshment practices, with six new directors
appointed since 2015, and an average Board tenure of ~6 years (as depicted below). </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g173656g0429155138726.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><FONT COLOR="#0070c0"><B>Voting Matters and Board Recommendations. </B></FONT></P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; text-indent:8%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">By now, you should have received the proxy statement for our upcoming Annual Meeting to be held on May&nbsp;18, 2021. I would
like to ask for your support by voting with the following recommendations of our Board of Directors: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="74%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-LEFT:1px solid #4f81bd; BORDER-TOP:1px solid #4f81bd; BORDER-RIGHT:1px solid #4f81bd; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:1px solid #4f81bd">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:1px solid #4f81bd; BORDER-RIGHT:1px solid #4f81bd">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:4pt ;BORDER-LEFT:1px solid #4f81bd; BORDER-RIGHT:1px solid #4f81bd; BORDER-BOTTOM:1px solid #4f81bd; padding-left:8pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#4f81bd"><B>FOR each</B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#4f81bd"><B>Director&nbsp;Nominee</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #4f81bd">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="padding-bottom:4pt ;BORDER-BOTTOM:1px solid #4f81bd">Item 1:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #4f81bd">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="padding-bottom:4pt ;BORDER-RIGHT:1px solid #4f81bd; BORDER-BOTTOM:1px solid #4f81bd; padding-right:2pt">Election of 11 directors to serve on our Board until the 2022 annual meeting of stockholders.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-LEFT:1px solid #4f81bd; BORDER-RIGHT:1px solid #4f81bd; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #4f81bd">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:4pt ;BORDER-LEFT:1px solid #4f81bd; BORDER-RIGHT:1px solid #4f81bd; BORDER-BOTTOM:1px solid #4f81bd; padding-left:8pt"><FONT COLOR="#4f81bd"><B>FOR</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #4f81bd">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="padding-bottom:4pt ;BORDER-BOTTOM:1px solid #4f81bd">Item 2:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #4f81bd">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="padding-bottom:4pt ;BORDER-RIGHT:1px solid #4f81bd; BORDER-BOTTOM:1px solid #4f81bd; padding-right:2pt">Advisory vote to approve our executive compensation.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" STYLE="BORDER-LEFT:1px solid #4f81bd; BORDER-RIGHT:1px solid #4f81bd; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #4f81bd">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:4pt ;BORDER-LEFT:1px solid #4f81bd; BORDER-RIGHT:1px solid #4f81bd; BORDER-BOTTOM:1px solid #4f81bd; padding-left:8pt"><FONT COLOR="#4f81bd"><B>FOR</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #4f81bd">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="padding-bottom:4pt ;BORDER-BOTTOM:1px solid #4f81bd">Item 3:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #4f81bd">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" STYLE="padding-bottom:4pt ;BORDER-RIGHT:1px solid #4f81bd; BORDER-BOTTOM:1px solid #4f81bd; padding-right:2pt">Ratification of Ernst&nbsp;&amp; Young LLP as our independent registered public accountants.</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">As you consider your vote, below is a summary of our corporate governance and compensation
practices and a snapshot of our achievements in 2020: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><U>We are committed to corporate governance best practices, informed by
stockholder engagement, and overseen by our highly experienced and independent Board.</U> </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; " COLOR="#0070c0">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">Our Board consists of a <B><FONT COLOR="#0070c0">diverse group of highly qualified leaders</FONT></B> in their
respective fields. Many of our directors have: </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify">Senior leadership experience at large companies and have gained significant and wide-ranging management
experience. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify">Public company experience, an understanding of corporate governance practices and trends, and bring a unique
perspective to the Board. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify">Extensive scientific and healthcare expertise relevant to our industry, including pioneering scientific
research in the areas of oncology and cardiology. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; " COLOR="#0070c0">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">Our <B><FONT COLOR="#0070c0">lead independent director</FONT></B>, Robert A. Eckert, has substantial and
specific duties and has been elected by our Board to serve as the lead independent director in 2021 subject to his <FONT STYLE="white-space:nowrap">re-election</FONT> to the Board by stockholders. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; " COLOR="#0070c0">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">We have a <B><FONT COLOR="#0070c0">highly independent Board</FONT></B> (10 of our 11 director nominees are
independent) and only independent Board members serve on key standing committees<SUP STYLE="font-size:85%; vertical-align:top">(</SUP><SUP STYLE="font-size:85%; vertical-align:top">3</SUP><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #5c6267;width:21%">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman; " ALIGN="left">Key standing committees of the Board include the Audit, Compensation and Management Development, Corporate
Responsibility and Compliance, and Governance and Nominating Committees. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; " COLOR="#0070c0">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">We have a long-standing practice of <B><FONT COLOR="#0070c0">stockholder engagement</FONT> </B>throughout the
year and at our Annual Meeting. Since our 2020 annual meeting of stockholders, we have engaged in governance-focused outreach activities and discussions with stockholders owning ~54% of our outstanding shares. </P></TD></TR></TABLE>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify"><B><U>Our Board has a history of responsiveness to stockholder feedback.</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:11pt; font-family:Times New Roman">Stockholders elect our Board annually by majority voting and have rights to act by special meeting, written consent, and proxy access. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify"><B><U>We executed on our strategic priorities in 2020.</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Our strategy includes a series of integrated activities to strengthen our long-term competitive position in the industry.
Select 2020 activities that support the execution of our strategic priorities and delivery of performance are summarized below (and discussed in further detail in our 2021 proxy statement): </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; " COLOR="#0070c0">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">Discovering and advancing <B><FONT COLOR="#0070c0">innovative medicines</FONT></B> that address important
unmet medical needs. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="left">We successfully integrated our acquisition of <B><FONT COLOR="#0070c0">Otezla<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP></FONT></B>. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify">We executed key clinical studies and advanced an innovative <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> pipeline delivering positive registration-enabling results, including for<B> <FONT COLOR="#0070c0">sotorasib</FONT></B> (our KRAS<SUP STYLE="font-size:85%; vertical-align:top">G12C</SUP> small
molecule inhibitor being investigated as a treatment for a variety of solid tumors) and <FONT COLOR="#0070c0"><B>tezepelumab</B></FONT><SUP STYLE="font-size:85%; vertical-align:top">(</SUP><SUP STYLE="font-size:85%; vertical-align:top">4</SUP><SUP
STYLE="font-size:85%; vertical-align:top">)</SUP> (an investigational therapy that blocks the action of thymic stromal lymphopoietin (TSLP), an epithelial cytokine that plays a key role across the spectrum of asthma inflammation). <B></B>The U.S.
Food and Drug Administration (FDA) granted <B><FONT COLOR="#0070c0">Breakthrough Therapy designation for both</FONT> <FONT COLOR="#0070c0">sotorasib and tezepelumab</FONT></B>. Breakthrough Therapy designation is a process designed to expedite the
development and review of drugs that are intended to treat a serious condition. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify">We continued to advance our <B><FONT COLOR="#0070c0">early pipeline</FONT></B>. We formed eight new product
teams (formed when a molecule has been judged to have the potential to be safe and effective in humans), initiated six <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> studies, and advanced two programs
through our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">early-to-late</FONT></FONT> stage portal. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; " COLOR="#0070c0">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">Developing <B><FONT COLOR="#0070c0">branded biosimilars</FONT></B>. </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify">We <B><FONT COLOR="#0070c0">launched AVSOLA</FONT></B><FONT COLOR="#0070c0">&reg;</FONT><B></B> (biosimilar
infliximab (Remicade&reg;<SUP STYLE="font-size:85%; vertical-align:top">(</SUP><SUP STYLE="font-size:85%; vertical-align:top">5</SUP><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>)) and, in 2020, we received approval of <B><FONT
 COLOR="#0070c0">RIABNI</FONT><FONT COLOR="#0070c0"><SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP></FONT></B> (biosimilar rituximab (Rituxan&reg;<SUP STYLE="font-size:85%; vertical-align:top">(</SUP><SUP
STYLE="font-size:85%; vertical-align:top">6</SUP><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>)) and launched it in 2021. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; " COLOR="#0070c0">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt"><B><FONT COLOR="#0070c0">Transforming Amgen</FONT></B> for the future. </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify">We continued to <B><FONT COLOR="#0070c0">realize gross productivity savings</FONT></B> ($304&nbsp;million in
2020) which we reinvested in our business. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; " COLOR="#0070c0">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">Adhering to a disciplined approach to <B><FONT COLOR="#0070c0">capital allocation</FONT></B> while <B><FONT
 COLOR="#0070c0">investing for long-term growth</FONT></B>. </P></TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify">We <B><FONT COLOR="#0070c0">invested $4.2</FONT>&nbsp;<FONT COLOR="#0070c0">billion in research and
development</FONT>, <FONT COLOR="#0070c0">$0.6</FONT>&nbsp;<FONT COLOR="#0070c0">billion in capital projects</FONT></B>, and <B><FONT COLOR="#0070c0">$3.35</FONT>&nbsp;<FONT COLOR="#0070c0">billion in BeiGene, Ltd.</FONT></B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify">We also <B><FONT COLOR="#0070c0">returned in excess of $7</FONT>&nbsp;<FONT COLOR="#0070c0">billion of
capital to stockholders</FONT></B> in the form of dividends paid ($3.8 billion) and repurchases of our Common Stock ($3.5 billion). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; " COLOR="#0070c0">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">Expanding our <B><FONT COLOR="#0070c0">global geographic reach</FONT></B>.<FONT COLOR="#0070c0"><B></B>
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify">We began our <B><FONT COLOR="#0070c0">strategic collaboration with BeiGene, Ltd.</FONT></B> to expand our
oncology presence in China. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-size:7.5pt" COLOR="#0070c0"><SUP STYLE="font-size:85%; vertical-align:top">&#8718;</SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt"><B><FONT COLOR="#0070c0">XGEVA</FONT></B><FONT COLOR="#0070c0">&reg;</FONT><B></B> and
<B><FONT COLOR="#0070c0">BLINCYTO</FONT><FONT COLOR="#0070c0">&reg;</FONT></B> were approved in China and <B><FONT COLOR="#0070c0">KYPROLIS</FONT><FONT COLOR="#0070c0">&reg;</FONT></B> is under review. </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="17%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-size:7.5pt" COLOR="#0070c0"><SUP STYLE="font-size:85%; vertical-align:top">&#8718;</SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt"><B><FONT COLOR="#0070c0">XGEVA</FONT></B> was added to the National Reimbursement Drug List in China.
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify">We established our <B><FONT COLOR="#0070c0">wholly-owned affiliate in Japan</FONT> </B>with the acquisition
of Amgen Astellas BioPharma K.K. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; " COLOR="#0070c0">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">Successfully operating our <FONT COLOR="#0070c0"><B>next-generation biomanufacturing</B></FONT> facility in
Singapore since 2017 and delivering <FONT COLOR="#0070c0"><B>cost and environmental efficiencies</B></FONT>. Success of our facility in Singapore, along with U.S. corporation tax reform, led to our building a second such plant in <FONT
 COLOR="#0070c0"><B>Rhode Island, our first U.S.</B></FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #5c6267;width:21%">&nbsp;</P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP> Being developed in collaboration with AstraZeneca plc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP> Remicade is a registered trademark of Janssen Biotech, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP> Rituxan is a registered trademark of Biogen Inc. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">
<B><FONT COLOR="#0070c0">next-generation biomanufacturing plant</FONT></B> that, upon approval by global regulatory authorities, will expand our manufacturing capacity, while also delivering
these efficiencies. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="justify">Our next-generation biomanufacturing approach dramatically reduces the scale and costs of making biologics,
<B><FONT COLOR="#0070c0">vastly reducing water and energy use</FONT></B>, while maintaining a reliable, high-quality, compliant supply of medicines. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><U>Our financial performance was strong despite the effects of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic.</U> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; " COLOR="#0070c0">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">For 2020, particularly during the initial stages of the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic, we experienced changes in demand for some of our products as physician-patient interactions were interrupted, which led to delays in diagnosis and treatment with varying degrees of impact across our portfolio. However, despite the effects
of the pandemic, <B><FONT COLOR="#0070c0">we outperformed our budgeted financial targets</FONT> </B>(established in advance of the onset of the pandemic) as we drove product volume growth (including increases in
<B><FONT COLOR="#0070c0">EVENITY</FONT><FONT COLOR="#0070c0">&reg;</FONT>, <FONT COLOR="#0070c0">Repatha</FONT><FONT COLOR="#0070c0">&reg;</FONT>, <FONT COLOR="#0070c0">Aimovig</FONT><FONT COLOR="#0070c0">&reg;</FONT>, </B>and <B><FONT
 COLOR="#0070c0">Prolia</FONT><FONT COLOR="#0070c0">&reg;</FONT></B> sales) and, following our successful integration, delivered strong <B><FONT COLOR="#0070c0">Otezla</FONT></B> sales in its first full year in our product portfolio.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; " COLOR="#0070c0">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">Our <FONT STYLE="white-space:nowrap">non-GAAP</FONT><SUP STYLE="font-size:85%; vertical-align:top">(</SUP><SUP
STYLE="font-size:85%; vertical-align:top">7</SUP><SUP STYLE="font-size:85%; vertical-align:top">) </SUP>net income performance also benefited from our strong sales performance, as well as our cost efficient mitigation of the challenges and risks of
the pandemic, and continued savings from efficiencies resulting from our strong performance on our productivity objective that was used to reinvest in our business. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; " COLOR="#0070c0">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">We delivered long-term stockholder value and returns, including three- and five-year total shareholder returns
of 44% and 63%, respectively, outperforming our peer group. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10.5pt" ALIGN="center">


<TR>

<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10.5pt">
<TD VALIGN="bottom" STYLE="BORDER:1px solid #000000; padding-left:8pt; padding-right:2pt" BGCOLOR="#dbe5f1"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.50em; margin-right:0.50em; text-indent:-1.00em; font-size:10.5pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#0070c0"><B>We established the goals for our annual cash incentive
award and long-term incentive equity award programs prior to the World Health Organization (WHO) declaration of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> global pandemic. Since then, we have not made any changes to these goals. Thus,
performance reported is against goals established prior to the pandemic.</B></FONT></P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><U>Executive compensation is aligned with our business strategy and is performance-based.</U> </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; " COLOR="#0070c0">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">We <B><FONT COLOR="#0070c0">pay for performance</FONT></B>, and pay outcomes reflect the achievements of our
Named Executive Officers, or NEOs, against our short- and long-term performance. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; " COLOR="#0070c0">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt"><B><FONT COLOR="#0070c0">76%</FONT> </B>of my 2020 target direct compensation and<B>
<FONT COLOR="#0070c0">70%</FONT> </B>of our other NEOs&#146; target direct compensation was <B><FONT COLOR="#0070c0">based solely on our Company&#146;s performance</FONT></B>. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; " COLOR="#0070c0">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt"><B><FONT COLOR="#0070c0">91%</FONT> </B>of my 2020 target direct compensation and<B>
<FONT COLOR="#0070c0">83%</FONT> </B>of our other NEOs&#146; target direct compensation<B> </B>is &#147;<B><FONT COLOR="#0070c0"><FONT STYLE="white-space:nowrap">at-risk</FONT></FONT></B>.&#148; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; " COLOR="#0070c0">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">Our Compensation and Management Development Committee approves Company goals each year that are designed to
focus our NEOs and all of our staff members on delivering our financial and operational objectives to drive annual performance, advance strategic priorities (discussed above), and position us for longer-term success. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><U>We have implemented compensation best practices, including:</U> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; " COLOR="#0070c0">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">A substantial <B><FONT COLOR="#0070c0">majority of our NEO compensation is performance-based</FONT></B>
(including 80% of total target equity, of which 50% are three-year performance awards and 30% are stock options). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; " COLOR="#0070c0">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">In addition to our existing annual cash incentive award recoupment policy, we recently updated <B><FONT
 COLOR="#0070c0">recoupment provisions</FONT></B> for misconduct to include forfeiture and cancellation of unvested or unexercised equity awards, and we have a <B><FONT COLOR="#0070c0">clawback policy</FONT></B> tied to financial restatements.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:SYMBOL; " COLOR="#0070c0">&#183;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:11pt">We have robust <B><FONT COLOR="#0070c0">stock ownership</FONT></B> and<B> <FONT COLOR="#0070c0">retention
guidelines</FONT></B>. </P></TD></TR></TABLE> <P STYLE="font-size:50pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #5c6267;width:21%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Non-Generally</FONT> Accepted Accounting Principles. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="justify"><B><U>Continued retention of Ernst&nbsp;&amp; Young LLP as our independent registered public
accountants is in the best interest of the Company and its stockholders.</U> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Our Audit Committee periodically
considers whether there should be a rotation of our independent registered public accountants. Each year, the Audit Committee evaluates the performance of the independent registered public accountants and determines after such evaluation whether to <FONT
STYLE="white-space:nowrap">re-engage</FONT> the current independent registered public accountants. Based on this evaluation, the Audit Committee believes that the continued retention of our independent registered public accountants is in the best
interests of the Company and its stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*** </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:8%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">This year, after careful consideration, in light of the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and
our successful 2020 virtual meeting of stockholders, our 2021 Annual Meeting of Stockholders will be held solely by remote communication via the internet. Of course, we will afford stockholders the same rights to participate in the virtual meeting
as they would have had at an <FONT STYLE="white-space:nowrap">in-person</FONT> meeting. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; text-indent:8%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">I realize there are many demands
on your time and want to thank you for your attention to these important issues. We would welcome the opportunity to discuss any of the voting matters in our proxy statement with you. Please do not hesitate to contact Arvind Sood, Vice President,
Investor Relations, by telephone at (805) <FONT STYLE="white-space:nowrap">447-1060</FONT> or via email at investor.relations@amgen.com with any questions. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:55%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Sincerely, </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:55%" ALIGN="justify">


<IMG SRC="g173656g0429155138860.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:55%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Robert A. Bradway </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:55%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Chairman of the Board, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:55%; font-size:11pt; font-family:Times New Roman" ALIGN="justify">Chief Executive Officer and President </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman">&laquo;SECONDNAME&raquo; </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g173656g0429155138547.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g173656g0429155138547.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !( LX# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1?\ Q-']GWW_ $&;G_OU%_\ $T :5%9O]GWW_09N?^_47_Q-']GWW_09N?\
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M6EA$+O4I95>9@P4 #L"Q' KT'^S[[_H,W/\ WZB_^)H_L^^_Z#-S_P!^HO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LRZDF%XEPF3
M#$VQE!/(/4XQVXK3K/>_D$=Q,JKY<#["I'+8.#SVH KM>7H9B&& 3@>7V#8_
ME2?VE<;Y.FU3@@(<CGJ..1C':K:ZK;MGAU]-PQDYQ@4C206UDUS;P@,P^1&^
M7)]/:@"&*ZN_M$:NP9"ZJ<1D9!4G//O6K5'^U(!#%)AV$B;_ )1G [TIU. +
MDB3.<%<<CG'\S0!=HJE_:<&X!5D;<0%VKD-U_P *5[X,MKY !-R?E+#@#&<X
MH N455:[\A_+F^9R1CRU[$X!(^M1#5H7\O;'(=Y7&0!P03GK[&@"_15)=2A=
MU54E8N<+A>#QG--GNKA+BX2,1%88A( P.6SGC.>.GI0!?HK/CU2.8(8TD&65
M263C)&<=?0BI/[2@\I9 '(89 QSWX^O'2@"Y12*P=0PS@C(R,4M !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5GR-8^?(C^9N)W.@1\''?IBM"JDEO*U\9ALV&$IR><Y^E #%L+
M.XB$BJY5N00S \G.?:K(@0>7]X[.F6)_/UK+CTNXCP/W13 W)N.&.,9Z4O\
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MX'^>X!M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5AW$]TMU.(W<KSMP>1R,Y'IC.#110 IDE?&VXRJS?
M)&9&#2+GL0<\?B*L7US+YD'D)(T8D 9HV7!//!YHHH C226:6[%REQ&J@,%$
MFW\ 5-33MY&E^7Y[>9&%R2YW=1U.<T44 5;R>[62;R6?S0^%4'^#RR<X^N.?
M6HWGG$DH65_(",8V#'E]JX&>_.>*** -R(L8D+_>(&?K3Z** "BBB@ HHHH
***** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g173656g0429155138726.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g173656g0429155138726.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "^ I4# 2(  A$! Q$!_\0
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MUM<J[%?+"&'!XP=Q+>^17:5G4INF[,UI58U%>(4445F:!1110 4444 %%%%
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MBKG..Q)Z'M2POJK3)Y\-HD6?GV2,Q_#@40?\AJ\_ZY1?S>K] !1110 4444
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M9&O15:SU&SU!&>SN8IU4X8QMG!JS4M-.S*335T%%%%(84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7+Z]XH^S.]EIQ5K@</*>5C_Q-/\4ZXUG&
M+&U;%S*,LP_Y9KZ_4UQ2J%7 KKH4.;WI;'-6JV]V(K%I)6EE=I)6Y9W.2:**
M*[CE"L'Q7_QXP?\ 73^E;U8/BO\ X\8/^NG]*UI?&C#$_P *7H<G1117J'SX
MH)5@RD@CD$=J]#\'_$>>R>.QUIS+;'Y5N#RR?7U%<%:6=Q?3^1;1&20C.T$#
MC\:CEBD@E>*5"DB':RGJ#6%:C3K+DD=-"O5H/GAM^!].QR)-$LL3AT<95E.0
M13Z\>^'7C%]/NDT>_ES:2G$+L?\ 5MZ?0U[#7S>(H2H3Y9'U.&Q$<13YXA11
M16!T!1110 5R&N^*FWO::6XXXDN>H!]%]_>E\5ZXP9M+M'(8C_2)%/(!_A'N
M>]<F %4 # '05V4*%_>D<M:K;W8ACYF<DL['+,QR2?<TM%%=QS!7+^+?]?9_
M[C?S%=17+^+?]?9_[C?S%:T/XB.;%_P9'.T=>@HK>\*7EO8W\LMS=+ @0$ I
MGS"#G;GL/6O0G)QBVE<\2G%3DHMV,2&:6WF6:&1HY$.5=#@@UZIX,^)'VF2/
M3M<=5D/RQ71X#'T;T/O7EEPP>YE<;<,Y(VC Z]O:HZQKX:%>-I+4WP^*J8>=
MXO3L?4?49%%>:?#;QDUT%T/49-TRK_HTK'E@/X3[CM7I=?-UJ,J,W"1]50K1
MK04XA11161L%%%% !1110 5S/C[5WT?PC=O 6^UW.+6W"#+%W.W@=R!D_A73
M5EZ[>Z7IEE'?ZJ%\F"53&Q3<5D)VK@>O./QH8T>?^'_$MWI7A*ZABEE8:)J"
M+.;M#YK63L#N(/((#'G_ &:+[QWX@2*U:W2)?M45Q>PNR##1*^V-.2.JX)/7
MD5V^F7^@^(#?/:I')(56*[62(JY7!P&![8SBM";3M-GMH4FMK=X80/*#*"J
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MRO[B/K%'^9?>=%15:PU"UU.T6ZLYEEA;[KKT-6:S::=F:IIJZ"BBBD,****
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ML/%QHQ3[(Z6BBBLC8**** "BBB@ HHHH **** "H;NVCO+26VE&4D4J:FHH
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MQ:SJ*7%U.5BCP42) KY'J_7'M4&@>%%T75;J^-P)&E7RXT52%1<YZ$GOZ8H
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M?,JIB7LY=^I>_P"$]\3_ /05D_[X7_"C_A/?$_\ T%9/^^%_PJB/#>KMI/\
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M/LEM_P ^\7_? H^R6W_/O%_WP*/[67\GX_\  #^Q7_/^'_!/F.BOIS[);?\
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@RVL=N"P#PTW+FO<6BBBN ]$**** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g173656g0429155138860.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g173656g0429155138860.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  C -T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#WRBJ]W>V]
MDB/<2"-7<(I/J>E<OX?\0W^O^,-36(!='LT$2$#_ %DF>30!V%%%<?XA\8RV
M/BG3?#NF6ZW-]<L'FSTBC[DT =A129&[;D9';-+D4 %%0"]MC>_8Q,AN-GF>
M6#SMSC-3T %%%,,T2RK$9%$C#*KGDT /HKE?'7B1M!T*9;-@=1F4B%<\K_M'
MV%;FC?:/[$L?M;E[@PJ9&/=B.: +U4-:UBTT'2;C4KV0)!"N3ZD]@/<U?) &
M2<#UKSCQ,(_%WC2UT22=$TG2RMS>$L ))/X4_K0!WVGW?V_3K>\$;1B:,.$?
MJ,^M6:KVMW9W V6L\4@08(C8' J971\[6#;3@X/0T .H) &3P!3!-$TAC61"
MX&2H/(KFO&VJ&UTM;&*;RIKPE2X/W(P,NWY4 ;UCJ=EJ0E-E<QSB)]CE&SM;
MTJCXDUY?#VE_:_LTEU(SB.."+[SL:Y7P=-8>%_"MQJUWBWCO9C)%%_$R]% '
M<G^M=/J]F->TZ+[-,(KN!TN(\\E&QD!A0!?TK48=7TRWOH,^7,FX ]0>X/TJ
MY7DVC>-IO"F@W1U'3G>(WTJ0/"PVLV>@]LYH\*?$F[U"YU+4M1G0:5;6Y>0!
M-HC?/" ]SB@#UFBN)E^)>E1>'$U'!>Y>(R"UC^9E],GM5O2/%-WK>DVTEC:"
M2YE0-(_2.,GMGO0!U,DL<,9>5U1!U9C@"N=N/%L<LQM]'LYM1F_O(-L8^K&K
M": UVZS:M<M=..1$.(Q^%;$,$-O&$AC2-1T"C% '*W.E>*M7LYQ<ZI%IY="(
MXK5>0?=CS6KX?\.P:+H-KIS,TS1+EY&8DNY^\?SK9H% 'E7Q;\0R"XTKP[I?
M[[4[B</Y:]5'8FG:OKA^$WAO3+<6XF:8E[B4_P 3]P/>J.F>'+SQ;XSUCQE:
MRK!+;SB#3V<?*^SAL^QZ5M:QX"UGQJT \3ZA#%;6\F]+>T7()]R: +S>.;S5
MM-\_0M,E*F+S&N;@;8T&,GZUS?P^UW3#H6I^,=7N86U:665&=F&2J?="CTKT
MRZT>&;P_+I$),,+0>0I4?=&,5@Z1\-?#>EZ-%IYL(Y]J;6DD'+D]3]: . \-
M>-IH?[5UZ1I[NZN(CY5KG(7&3D^@ KJ)M4N=$^&5SJU[?8U&]3S_ +W*E\85
M1["NKT_PCHFEZ?/96EC''%.A20]68$8ZUS>L_#K3DT"^$$=S>W/D%+=)I"P3
ML-HH P/AUX5;6[.Z\07=Y>QRW$I2W;S3N$8_Q-=ROAF_B(\OQ!>8'9@#6IH.
MGII>@6%BD?EB&!5*^AQS^M:- &3%HTH(\_4;B;V)Q6-XULOL6EQ:[:S>5<Z4
M3*"S<.G\2GZUU]<[XN\.2^*+.UL#<>59B=9+E.\J#^&@#S/1FD\7;==O'S=:
MO>K;PP9_U$"'<>/?%>UL\<*HK,J D*N3C)]*Y1/ UM:^,[/7+)Q!;PPLCVP'
MREL8##T.*Z:ZLK>\,)GCW^3()$YZ,.] ',?$W5)=(\!W]S 2)CM2/;U))'%<
ME9V?A71+.&;Q,[+JD]K]MGWN0&SV]SVKTW5]'LM;M%M;Z/S(ED60+G^)3D5#
MJGAO1M:DADU'3X;AH1B,NN<"@#S#P[K)QJ5YX<T]FO;U<0QJ#Y<$:]"Q]3UJ
M32O$6MV'@M[73--O+O57W27=RZD!'8\XSUQ7K-K96MC"(K6WCAC'144 5,JJ
MHPJ@?04 >(^$?!GC6VU"\ULZE+ LT9&+CYG(ZY"]JHV?A'QGXIF6]FGEC(9E
ME:\. Z[N@'88KWVB@#S#4_A_K3OI5U%>1W=[;R[F,IQ'&,8&U?:GZ?HOBW2[
MC4K"$>;+?3;WU.1N%7&.!ZBO3** ,)/"6E-H=KI5W;K<0VYW#?W?NWU-9R?#
MCP^E])/]G8PR-N-MG]WGUQ774'D8H \IUC3K;4;=;/2[:*UL;BZ%K$(UPTV#
M\[$_W0!7IUE96^GV<=K:Q+'#&H5548%<=X<\.ZI8^)2MZJMIM@LALI >6,C9
M.1Z@<5W- !1110 4HI*44 9NB*J::JHBJ-[<* !UK1HHH 6DHHH **** "BB
MB@ H[444 ':BBB@ HHHH **** "BBB@ HHHH **** "CM110 4444 % HHH
"_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
